Study to Evaluate the Efficacy and Safety of K-877-ER and CSG452 in Participants With NASH With Liver Fibrosis
Phase
2Span
177 weeksSponsor
Kowa Research Institute, Inc.Kure, Hiroshima
Recruiting
Kure
Recruiting
A Study of LY3556050 in Adult Participants With Diabetic Peripheral Neuropathic Pain
Phase
2Span
95 weeksSponsor
Eli Lilly and CompanyKure, Hiroshima
Recruiting
A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)
Phase
3Span
265 weeksSponsor
Eli Lilly and CompanyKure, Hiroshima
Recruiting
LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis
Phase
3Span
236 weeksSponsor
Boehringer IngelheimKure
Recruiting
A Study to Investigate Long-term Safety and Tolerability of Itepekimab in Participants With COPD
Phase
3Span
151 weeksSponsor
SanofiKure, Hiroshima
Recruiting
LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis
Phase
3Span
376 weeksSponsor
Boehringer IngelheimKure
Recruiting
A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight
Phase
3Span
110 weeksSponsor
Eli Lilly and CompanyKure, Hiroshima
Recruiting
A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE
Phase
3Span
199 weeksSponsor
Janssen Research & Development, LLCKure
Recruiting
1-9 of 9